HGS drug doesn't extend survival for lung cancer patients in study

03/18/2010 | Reuters

Cancer drug mapatumumab did not boost the efficacy of chemotherapy drugs paclitaxel and carboplatin in improving progression-free survival for patients with nonsmall-cell lung cancer during a midstage trial. Human Genome Sciences, maker of mapatumumab, tested the combination as a first-line therapy.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC